Dr Chiramel is a highly experienced Consultant Oncologist specialising in the treatment and long-term management of breast cancer and neuroendocrine tumours (NETs). She works at The Chiltern Hospital, providing personalised, evidence-based cancer care for patients with both early-stage and advanced disease.

Following her medical qualification, Dr Chiramel completed specialist oncology training within leading UK teaching hospitals, gaining extensive experience in systemic anti-cancer therapies including chemotherapy, endocrine therapy, targeted therapies, immunotherapy, and supportive cancer care. She has developed particular expertise in the management of hormone receptor-positive, HER2-positive, and triple-negative breast cancers, as well as well-differentiated and high-grade neuroendocrine malignancies.

Dr Chiramel currently holds a Consultant position within the NHS and works closely within specialist multidisciplinary teams to deliver tailored treatment plans that focus on achieving the best possible clinical outcomes while maintaining quality of life. Her approach combines clinical excellence with compassionate, patient-centred care, ensuring patients feel fully supported throughout their treatment journey.

Alongside her clinical work, Dr Chiramel is actively involved in teaching, training, and service development within the NHS. She regularly contributes to educational programmes, multidisciplinary meetings, and trainee supervision, and maintains a strong interest in clinical research and advances in oncology care. She frequently attends national and international oncology conferences to remain at the forefront of emerging therapies and evolving cancer treatments.

Dr Chiramel is recognised for her approachable and reassuring manner, placing great importance on clear communication, shared decision-making, and holistic support for both patients and their families.

Clinical Interests:

• Early and advanced breast cancer 
• Hormone receptor-positive breast cancer
• HER2-positive breast cancer
• Triple-negative breast cancer
• Systemic anti-cancer therapies, including chemotherapy, Immunotherapy, endocrine therapy and targeted therapies 
• Metastatic breast cancer management 
• Neuroendocrine tumours (NETs) 
• Lung carcinoid and GEPNETs 
• High-grade neuroendocrine carcinomas
• Special interest in immune oncology and geriatric oncology.

• Royal College of Physicians (RCP)
• Medical Defence Union (MDU)
• British Medical Association (BMA)
• European Society for Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)
• Association of Cancer Physicians (ACP)
• UK and Ireland Neuroendocrine Tumour Society (UKINETS)
• European Neuroendocrine Tumor Society (ENETS)